Mark Litton
Chief Executive Officer bij ATHIRA PHARMA, INC.
Vermogen: 631 731 $ op 29-02-2024
Profiel
Mark J.
Litton founded Lundbeck Seattle BioPharmaceuticals, Inc. Currently, he is President, Chief Executive Officer & Director at Athira Pharma, Inc. Dr. Litton is also on the board of Lumen Bioscience, Inc.
Dr. Litton previously held the position of President & Chief Operating Officer at Alpine Immune Sciences, Inc., Manager-Business Development at Sirna Therapeutics, Inc., Vice President-Business Development of Celltech Group Plc, Vice President-Business Development of Chiroscience Group Plc, Secretary, Treasurer & Chief Business Officer at Lundbeck Seattle BioPharmaceuticals, Inc. and Research Associate at DNAX Research, Inc.
He received a doctorate from the University of Stockholm, an MBA from Santa Clara University and an undergraduate degree from the University of California, Santa Cruz.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
ATHIRA PHARMA, INC.
0.43% | 15-02-2024 | 164 086 ( 0.43% ) | 631 731 $ | 29-02-2024 |
Actieve functies van Mark Litton
Bedrijven | Functie | Begin |
---|---|---|
ATHIRA PHARMA, INC. | Chief Executive Officer | 16-06-2021 |
Lumen Bioscience, Inc.
Lumen Bioscience, Inc. Pharmaceuticals: OtherHealth Technology Lumen Bioscience, Inc. operates as a clinical stage biotechnology company which engages in the manufacture of therapeutic biologics for oral delivery. It focuses on the development of the blue-green algae Spirulina as an industrial scale production platform. The company was founded by Brian Finrow and James Roberts in 2017 and is headquartered in Seattle, WA. | Director/Board Member | - |
Eerdere bekende functies van Mark Litton
Bedrijven | Functie | Einde |
---|---|---|
ALPINE IMMUNE SCIENCES, INC. | President | 16-04-2019 |
ALDER BIOPHARMACEUTICALS, INC. | Founder | 01-08-2018 |
Celltech Group Plc
Celltech Group Plc BiotechnologyHealth Technology Celltech Group Plc was one of the leading European biotechnology company which is engaged in discovery and development of innovative drugs. The company was located in Slough, United Kingdom. | Corporate Officer/Principal | 01-01-2004 |
Sirna Therapeutics, Inc.
Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sirna Therapeutics, Inc. creates potent and stable siRNA compounds that are delivered into human cells resulting in the silencing of genes and viruses responsible for human diseases. The firm creates RNAi- based therapies to treat patients. The company was founded in 1992 and is headquartered in San Francisco, CA. | Corporate Officer/Principal | 01-01-1999 |
DNAX Research, Inc. | Corporate Officer/Principal | 01-01-1994 |
Opleiding van Mark Litton
Santa Clara University | Masters Business Admin |
University of California, Santa Cruz | Undergraduate Degree |
University of Stockholm | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
ATHIRA PHARMA, INC. | Health Technology |
ALPINE IMMUNE SCIENCES, INC. | Health Technology |
Bedrijven in privébezit | 6 |
---|---|
Sirna Therapeutics, Inc.
Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sirna Therapeutics, Inc. creates potent and stable siRNA compounds that are delivered into human cells resulting in the silencing of genes and viruses responsible for human diseases. The firm creates RNAi- based therapies to treat patients. The company was founded in 1992 and is headquartered in San Francisco, CA. | Commercial Services |
Celltech Group Plc
Celltech Group Plc BiotechnologyHealth Technology Celltech Group Plc was one of the leading European biotechnology company which is engaged in discovery and development of innovative drugs. The company was located in Slough, United Kingdom. | Health Technology |
Chiroscience Group Plc | Commercial Services |
Lundbeck Seattle BioPharmaceuticals, Inc.
Lundbeck Seattle BioPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lundbeck Seattle BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Its product includes Eptinezumab, is an investigational monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA. | Health Technology |
DNAX Research, Inc. | |
Lumen Bioscience, Inc.
Lumen Bioscience, Inc. Pharmaceuticals: OtherHealth Technology Lumen Bioscience, Inc. operates as a clinical stage biotechnology company which engages in the manufacture of therapeutic biologics for oral delivery. It focuses on the development of the blue-green algae Spirulina as an industrial scale production platform. The company was founded by Brian Finrow and James Roberts in 2017 and is headquartered in Seattle, WA. | Health Technology |